Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage.
Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.
Location: United States, California, Emeryville
Employees: 51-200
Total raised: $45M
Founded date: 2006
Investors 2
| Date | Name | Website |
| - | Acorn Paci... | acornpacif... |
| - | Cloudstone... | cloudstone... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.03.2020 | Series E | $45M | - |
Mentions in press and media 6
| Date | Title | Description |
| 18.03.2020 | Daily funding roundup - March 18th, 2020 | Rivet has raised $8.25M; ZeroNorth closed $10M; Eureka Therapeutics landed $45M LumenAd: LumenAd is a management platform. LumenAd has raised $2 million in seed funding led by Next Frontier Capital. Read more Fiscozen: Fiscozen is a digital... |
| 18.03.2020 | Eureka Therapeutics scores $45M for cancer treatment | Eureka Therapeutics, a developer of T-cell therapies for solid tumors, has announced the closing of a $45 million Series E led by Lyell Immunopharma, with participation from new and existing backers. Founded in 2006 and based in Emeryville,... |
| 17.03.2020 | Eureka Therapeutics Closes $45M Series E Financing | Eureka Therapeutics, Inc., an Emeryville, Calif.-based clinical stage biotechnology company developing novel T cell therapies for solid tumors, closed a $45m Series E financing. The round was led by Lyell Immunopharma and joined by a syndic... |
| 15.02.2019 | J&J R&D vet Peter Tummino joins the Big Pharma exodus, leaping to Nimbus as CSO; Cadent taps Jodie Morrison for CEO | → After spending the last 16 years as a researcher in Big Pharma, Peter Tummino is going biotech. Peter Tummino Nimbus reports that Tummino is joining the company as its new CSO after his last stint at J&J, where he w... |
| 23.01.2018 | Eureka Therapeutics Closes $60M Series D Financing | Eureka Therapeutics, Inc., an Emeryville, CA-based clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T cell therapies for the treatment of solid tumors, completed a $60m Se... |
| - | Healthcare startups netted a record number of mega-deals last quarter. Meet the 10 companies pulling in the most cash. | A KRY physician examines a patient. KRY This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Investors poured $14.6 billion into healthcare startups during the first quarter of 2020. Digital h... |